• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测 HCV 相关 ACLD 患者 SVR 后的临床病程:一项为期 5 年的前瞻性研究中肝硬度的作用。

Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study.

机构信息

Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.

Departmental Program "Diseases of the Liver and Biliary System", AOU Federico II, 80131 Naples, Italy.

出版信息

Viruses. 2024 Sep 10;16(9):1439. doi: 10.3390/v16091439.

DOI:10.3390/v16091439
PMID:39339915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11437428/
Abstract

The prediction of liver-related events (LRE) after sustained virological response (SVR) in HCV-advanced chronic liver disease (ACLD) patients is crucial. We aimed to evaluate incidence and risk factors of LRE in HCV-cirrhotic patients after SVR and to assess dynamic changes of liver stiffness in participants without LRE at the end of follow-up. We enrolled 575 consecutive patients with HCV-ACLD treated with DAAs and followed up for 5 years after SVR12. Overall, 98 (17%) patients developed any type of event, and HCC was the most frequent LRE. The incidence rate was 1.6 per 100 person-years (p/y) for both HCC and hepatic decompensation. Baseline LSM ≥ 20 kPa was the only independent predictor of hepatic decompensation, while LSM ≥ 20 kPa and male sex were independent predictors of HCC development. Among the 341 participants without LRE and with paired LSM, any LSM reduction was observed in 314 (92.1%), and half of them showed a decrease of LSM ≥ 20%. Among patients without LRE, 27.3% of participants without ≥20% LSM decrease at 2 years achieved the 5-year goal; in contrast, 31.6% of participants with ≥20% LSM decrease at 2 years lost it at 5 years. These findings provide evidence that baseline LSM is a tool to stratify patients at risk of developing LRE; the dynamic changes of LSM value suggest the need for monitoring this parameter over time.

摘要

预测 HCV-advanced chronic liver disease (ACLD) 患者持续病毒学应答 (SVR) 后与肝脏相关的事件 (LRE) 至关重要。我们旨在评估 HCV 肝硬化患者 SVR 后 LRE 的发生率和危险因素,并评估无 LRE 参与者在随访结束时肝硬度的动态变化。我们纳入了 575 例接受 DAA 治疗的 HCV-ACLD 连续患者,并在 SVR12 后随访 5 年。总体而言,98 例(17%)患者发生任何类型的事件,HCC 是最常见的 LRE。HCC 和肝失代偿的发生率均为 1.6 例/100 人年(p/y)。基线 LSM≥20 kPa 是肝失代偿的唯一独立预测因素,而 LSM≥20 kPa 和男性是 HCC 发展的独立预测因素。在 341 例无 LRE 且有配对 LSM 的参与者中,314 例(92.1%)观察到任何 LSM 降低,其中一半显示 LSM 降低≥20%。在无 LRE 的患者中,2 年内无 LSM 降低≥20%的患者中有 27.3%达到 5 年目标;相比之下,2 年内 LSM 降低≥20%的患者中有 31.6%在 5 年内失去了这一目标。这些发现为基线 LSM 是一种分层有发生 LRE 风险的患者的工具提供了证据;LSM 值的动态变化表明需要随时间监测该参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/2f16f6c9642e/viruses-16-01439-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/903c4c6614be/viruses-16-01439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/e31dfab34195/viruses-16-01439-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/2f16f6c9642e/viruses-16-01439-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/903c4c6614be/viruses-16-01439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/e31dfab34195/viruses-16-01439-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b214/11437428/2f16f6c9642e/viruses-16-01439-g003.jpg

相似文献

1
Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study.预测 HCV 相关 ACLD 患者 SVR 后的临床病程:一项为期 5 年的前瞻性研究中肝硬度的作用。
Viruses. 2024 Sep 10;16(9):1439. doi: 10.3390/v16091439.
2
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.口服抗病毒药物治疗后,丙型肝炎相关代偿性晚期慢性肝病患者肝脏相关事件的无创预测。
J Hepatol. 2020 Mar;72(3):472-480. doi: 10.1016/j.jhep.2019.10.005. Epub 2019 Oct 17.
3
Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.DAA 治疗后获得 SVR 的丙型肝炎慢性患者,治疗前肝脏硬度值低于 17.5 千帕斯卡者 HCC 发生率低。
PLoS One. 2020 Dec 10;15(12):e0243725. doi: 10.1371/journal.pone.0243725. eCollection 2020.
4
Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?非侵入性肝纤维化评估能否预测 HCV 患者持续病毒学应答后晚期随访的临床结局?
Clinics (Sao Paulo). 2024 May 10;79:100381. doi: 10.1016/j.clinsp.2024.100381. eCollection 2024.
5
Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.肝硬化退伍军人 HCV 清除后肝硬度测量与肝细胞癌风险预测。
Clin Gastroenterol Hepatol. 2024 Apr;22(4):778-788.e7. doi: 10.1016/j.cgh.2023.11.020. Epub 2023 Dec 5.
6
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.基于丙型肝炎病毒清除后的年龄和瞬时弹性成像肝脏硬度预测肝细胞癌。
Sci Rep. 2022 Jan 27;12(1):1449. doi: 10.1038/s41598-022-05492-5.
7
Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.直接作用抗病毒药物治疗的慢性丙型肝炎患者中肝硬度测量对肝细胞癌发展的影响:系统评价和事件时间荟萃分析。
J Gastroenterol Hepatol. 2021 Mar;36(3):601-608. doi: 10.1111/jgh.15243. Epub 2020 Sep 10.
8
Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.比较慢性丙型肝炎治疗患者中肝细胞癌非侵入性检测工具的预测能力
Dig Dis Sci. 2023 Jan;68(1):323-332. doi: 10.1007/s10620-022-07621-6. Epub 2022 Jul 27.
9
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.基于非侵入性标志物的模型预测丙型肝炎病毒先进纤维化病毒应答后极低的肝细胞癌风险。
Hepatology. 2020 Dec;72(6):1924-1934. doi: 10.1002/hep.31588. Epub 2020 Nov 10.
10
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.治疗后 LSM 而非治疗期间的变化可预测 HCV 治愈后 cACLD 患者的失代偿。
J Hepatol. 2024 Jul;81(1):76-83. doi: 10.1016/j.jhep.2024.03.015. Epub 2024 Mar 21.

本文引用的文献

1
Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication.丙型肝炎病毒根除后,随着时间的推移,肝细胞癌风险降低。
Aliment Pharmacol Ther. 2024 Feb;59(3):361-371. doi: 10.1111/apt.17802. Epub 2023 Nov 13.
2
Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.肝硬度测量中的动力学变化可预测晚期慢性肝病的结局。
Gastroenterology. 2023 Oct;165(4):1041-1052. doi: 10.1053/j.gastro.2023.06.030. Epub 2023 Jul 11.
3
Dynamic Changes in Non-Invasive Markers of Liver Fibrosis Are Predictors of Liver Events after SVR in HCV Patients.
慢性丙型肝炎病毒(HCV)感染者获得持续病毒学应答(SVR)后,非侵入性肝纤维化标志物的动态变化可预测肝脏事件。
Viruses. 2023 May 26;15(6):1251. doi: 10.3390/v15061251.
4
Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化患者肝脏硬度的动态变化可预测其并发症。
Dig Liver Dis. 2023 Nov;55(11):1472-1479. doi: 10.1016/j.dld.2023.04.018. Epub 2023 May 2.
5
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort.在 PITER 队列中对肝硬化患者 HCV 长期清除后发生肝细胞癌的风险进行分析。
Dig Liver Dis. 2023 Jul;55(7):907-917. doi: 10.1016/j.dld.2023.01.153. Epub 2023 Feb 10.
6
Non-invasive tests for clinically significant portal hypertension after HCV cure.慢性丙型肝炎治愈后临床显著门静脉高压的非侵入性检测。
J Hepatol. 2022 Dec;77(6):1573-1585. doi: 10.1016/j.jhep.2022.08.025. Epub 2022 Sep 5.
7
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识:门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
8
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.HCV 肝硬化患者 SVR 后肝及非肝相关结局的发生率。
J Hepatol. 2022 Feb;76(2):302-310. doi: 10.1016/j.jhep.2021.09.013. Epub 2021 Sep 27.
9
Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study.直接抗病毒药物治疗后丙型肝炎病毒肝硬化患者肝脏失代偿和肝细胞癌的危险因素:一项多中心前瞻性研究
Cancers (Basel). 2021 Jul 29;13(15):3810. doi: 10.3390/cancers13153810.
10
Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study.非侵入性评估晚期慢性丙型肝炎病毒 (HCV)相关肝病和持续病毒学应答 (SVR)患者的纤维化消退和门静脉高压:前瞻性纵向研究 3 年随访。
J Viral Hepat. 2021 Nov;28(11):1604-1613. doi: 10.1111/jvh.13587. Epub 2021 Oct 1.